Alzamend Neuro (ALZN) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on April 17, 2026, with seven director seats up for election and several key proposals on the agenda.

• Proposals include director elections, auditor ratification, executive compensation advisory vote, approval of a new equity incentive plan, equity issuances to insiders, a reverse stock split, and potential adjournment for further proxy solicitation.

• The Board recommends voting FOR all proposals and nominees.

Voting matters and shareholder proposals

• Shareholders will vote on seven proposals: electing seven directors, ratifying Haskell & White LLP as auditor, a non-binding say-on-pay vote, approving the 2025 Stock Incentive Plan, approving equity issuances to directors and officers, amending the certificate for a reverse stock split, and authorizing adjournment if needed.

• The Board recommends FOR all proposals.

• Shareholders can vote online, by phone, or by mail, and may change their vote before or during the meeting.

Board of directors and corporate governance

• Seven nominees, all current directors, are up for re-election; majority are independent per Nasdaq and SEC rules.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.

• The Board held two meetings in FY2025; all directors attended at least 75% of meetings.

• Board leadership is separate from management, with risk oversight distributed among committees.